Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VB 10.16

Next Previous
Drug Profile

VB 10.16

Alternative Names: VB10.16

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccibody
  • Developer Nykode Therapeutics; Roche
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Papillomavirus vaccines; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell modulators; B cell stimulants; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer
  • Phase I/II Cervical intraepithelial neoplasia; Squamous cell cancer

Most Recent Events

  • 21 Mar 2024 Efficacy data from a phase II trial in Cervical cancer released by Nykode Therapeutics
  • 24 Nov 2023 Nykode Therapeutics completes a phase II trial for Cervical cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Belgium, Bulgaria, Czech Republic, Germany, Norway, Poland (IM) (EudraCT2019-002328-33) (NCT04405349)
  • 30 Sep 2023 Phase-I/II clinical trials in Squamous cell cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease) in United Kingdom (IM) (NCT06016920)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top